Intrexon | XON - Current Assets


Intrexon reported $23.72M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
MannKind USD 251.16M 40.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Veracyte USD 522.17M 33.8M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026